Navigate to
-
Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...
-
Pharmacy Friends In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event Alex Cook...
PA Sub-Categories: Products Specialty drugs Technology Prime Article: Stories -
Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...
-
References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....
-
Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...
-
Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care
PA Sub-Categories: Products Specialty drugs Prime Article: Press Releases -
Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....
-
Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...